In a deal that Aspect Biosystems Ltd. CEO Tamer Mohamed suggested could mean science fiction coming to real life, the Vancouver, BC-based firm focused on bioprinted tissue therapeutics is teaming with Novo Nordisk A/S to develop allogeneic cell therapies for type 1 diabetes. The companies unveiled their partnership on 12 April, with Aspect getting $75m up front plus up to $650m in earnouts tied to as many as four programs.
Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
